F
at grafting to the breast fulfills an increased clinical demand for a biocompatible filler in contour refinement, volume adjustment, and tissue rejuvenation in both cosmetic and reconstructive procedures, and has been used for total breast reconstruction. [1] [2] [3] [4] [5] Although many clinical studies have reported on the efficacy of fat grafting for breast cancer patients in terms of its various indications, 2, [6] [7] [8] [9] technical advancements, 7,9-14 volume stability and graft survival, 5, 8, 9, 12, [14] [15] [16] [17] [18] [19] radiologic safety, 2, 3, 12, [20] [21] [22] 25, 26 and complication rates, 9, 12, 13, [23] [24] [25] [26] [27] few studies have focused on oncologic safety. Fewer still have adequate data and follow-up periods to reach meaningful conclusions. 9, 19, 20, 23, 24, [28] [29] [30] Others report outcomes for cosmetic breast patients only. 5, 26, 31, 32 Where oncologic safety is assessed, many reviews focus on radiologic sequelae interfering with mammographic surveillance.
confounding variables such as histology, resection margins, receptor status, and adjuvant treatments, which can only be corrected for by comparison with an appropriate control group. [35] [36] [37] Petit et al. 38 reported the first case-matched retrospective series (level IIb evidence). We aimed to replicate this research using the same study design and then systematically review other relevant published cohort studies to which our results could be compared.
PATIENTS AND METHODS
Between January of 2007 and August of 2013, 396 patients were treated with fat grafting to the breast at the Nottingham Breast Institute for a variety of indications, including breast asymmetry, contour deformity, correction of radiotherapy-induced fibrosis, and volume enhancement. Excluded from this study were benign conditions (n = 68), women whose primary oncologic surgery was performed elsewhere with missing cancer data (n = 51), disease recurrence before fat grafting (n = 35), and failure to identify a suitable case-control match (n = 31). Data for 211 patients (ductal carcinoma in situ, n = 27; invasive carcinoma, n = 184) treated for breast cancer between 1977 and 2013 were included.
For each of the 211 patients in the study population (fat grafting), two control subjects were matched from a prospective database of women who were treated for primary breast cancer at Nottingham Breast Institute who did not undergo fat grafting. Each control was matched for five variables: date of primary cancer operation (within 2 years), age (within 5 years), type of surgery, histology, estrogen receptor status, and disease-free interval by time of fat grafting (Table 1) . Further cancer variables were compared between the two populations to ensure homogeneity (Tables 2 and 3 ). Similar to the case-controlled series by Petit et al., 34 the selected control patient had a disease-free period (extrapolated time A′ to B′) at least as long as the interval between oncologic surgery and the fat grafting procedure (time A to B) of the corresponding study patient (Fig. 1) . If the matched control had a recurrence before the end of this estimated time interval, that patient was excluded, and another appropriate control was selected. The primary endpoint of the study was tumor recurrence, where the type and date were noted. The secondary endpoint was breast cancer-related death.
Data for women with recurrent disease before fat grafting intervention (n = 35) were collected for descriptive purposes and not included in the case-matched series, but were analyzed separately. Patients treated for breast cancer were followed annually with clinical examination and mammography for 2 to 5 years, depending on the primary pathologic condition (Fig. 1) .
Fat grafting was performed according to the Coleman technique 7, 16 without stem cell enhancement. Tumescence included 150 mg of levobupivacaine in 1 liter of 0.9% normal saline with 1:1,000,000 adrenaline injected with a blunt cannula. Donor-site selection was dependent on surgeon and patient preference but was most commonly the abdomen and upper thigh area. Fat was injected in thin strips. Some patients had more than one fat grafting procedure, with a mean of 1.28 per patient (range, one to four procedures).
A systematic literature review included all studies with adequate descriptions of oncologic events and follow-up, reporting on patients treated for breast cancer with subsequent fat grafting. Patients who had a recurrent event before the fat grafting intervention were excluded.
Statistical Analysis
The difference in prognostic variables between study and control groups was assessed using the chi-square test. The main outcomes were recurrent oncologic events in terms of local, regional, and distant recurrences and death. Logrank Kaplan-Meyer curves were used to calculate disease-free survival. Any event occurring simultaneously with a local relapse, such as a regional recurrence or synchronous metastases, was counted as a local event.
In case of no events, the endpoint of the study was censored at the last follow-up. Statistical significance was considered at a probability of p < 0.05.
The impact of fat grafting on risk of a recurrence was evaluated using the multivariate Cox proportion hazard regression model and expressed as hazard ratio with 95 percent confidence intervals (Tables 1 through 4) .
RESULTS
Patient characteristics and follow-up are presented in Tables 1 through 4 . The majority of patients in both the fat grafting and control groups were treated by mastectomy; of these, almost 50 percent were skin-sparing or nipple-sparing mastectomies. Although the breast-conserving surgery rate in the fat grafting group was 16.6 percent (35 patients), this included only one patient with ductal carcinoma in situ (0.7 percent) ( Table 3) . Tables 2 and 3 show the distribution of nonmatched variables in the fat grafting and control groups for invasive cancer and ductal carcinoma in situ. The populations are considered well matched, with human epidermal growth factor receptor 2 status (p = 0.013) and Herceptin (Genentech, Inc., South San Francisco, Calif.) treatment (p = 0.001) being the only different variables. This was most likely because of a large quantity of missing data in both groups as a result of nonroutine human epidermal growth factor receptor 2 testing before 2005.
Outcome Analysis
The cumulative incidence of local recurrence in the fat grafting and control groups was 0.95 percent and 1.90 percent, respectively (p = 0.744) ( Tables 5 and 6 ). The locoregional recurrence was equal between the fat grafting [four of 211 (1.9 percent)] and control [eight of 422 (1.9 percent)] groups, at 0.7 percent per year (Table 6 ). The characteristics of four women experiencing locoregional recurrence events after the fat grafting intervention are shown in Table 7 ( Tables 5 through 7 and Figs. 2 
and 3).

Locoregional Recurrence or Distant Metastases before Fat Grafting
The mean age of the patients in this cohort (n = 35) was 42 years (range, 27 to 64 years) and mean follow-up after oncologic surgery and fat grafting was 170 months and 30 months, respectively, with a mean time to baseline of 140 months. There were 33 invasive cancers and two cases of ductal carcinoma in situ. Eleven patients (11 of 35) initially had a mastectomy, but all patients eventually underwent mastectomy following a recurrence, so all patient had a mastectomy before fat grafting. Table 8 demonstrates the recurrent events before fat grafting in this subgroup. Despite 40 percent of these patients having a previous ipsilateral local recurrence, no patient went on to have a further local event.
Three patients developed further recurrent events (8.6 percent). One patient developed a palpable supraclavicular node 20 months after the fat grafting intervention, one patient developed a distant metastasis 6 months after fat grafting, and one patient developed a new contralateral cancer (Table 8) . Table 9 compares this series and the series by Petit et al. 34 There was a significantly greater proportion of patients undergoing breast-conserving therapy in the series by Petit et al. compared with the current series (39 percent versus 17 percent).
Comparison with Case-Controlled Series in the Literature
DISCUSSION
The results of this study show no significant association between fat grafting and disease recurrence in women previously treated for breast cancer. This was the case both for locoregional recurrence (0.7 percent per year for both fat grafting and control groups) and for distant metastases (1.2 percent per year versus 0.9 percent per year).
These rates are lower than those reported in the only other case-controlled series, 38 where locoregional recurrence was 1.9 percent per year in fat grafting, 1.7 percent per year in controls and distant metastases, and 1.9 percent per year in both groups. This difference may be explained by the smaller number of breast-conserving surgery cases in our series.
Fat grafting after previous breast-conserving surgery for breast cancer may be the best model for understanding the interaction between the fat graft and breast parenchyma in addressing the safety of fat grafting. 37 In our series, most of the indications for fat grafting were in postmastectomy patients, although half of these patients received a skin-sparing or nipple-sparing mastectomy. For breast-conserving cases, the locoregional recurrence rate was higher in the fat grafting group compared with controls but not significantly so (2.1 percent versus 1.1 percent per year; p = 0.533). In the multicenter series by Petit et al., 24 comparable cumulative incidence curves were observed when breast-conserving surgery and mastectomy patients were analyzed separately. In their case-controlled series, Petit et al. 38 reported a locoregional recurrence of 2.2 percent per year in patients who had fat grafting after breast-conserving surgery, which was not significantly different from controls.
For the mastectomy group in our series, there was no significant difference in locoregional recurrence between fat grafting and control groups: 0.4 percent per year versus 0.6 percent per year (p = 0.848). Riggio et al. 30 reported a locoregional recurrence rate of 0.88 percent per year, Rigotti et al. 28 reported a locoregional recurrence rate of 0.75 percent per year, and Petit et al. 38 reported a locoregional recurrence rate of 1.4 percent per year for fat grafting after mastectomy (Table 10) . 24, [28] [29] [30] [38] [39] [40] [41] Unlike the series by Petit et al., 24, 38, 39 we observed no recurrences in patients treated with fat grafting following surgery for ductal carcinoma in situ. This could be attributable to a number of factors. There was a long disease-free interval between primary oncologic surgery and fat grafting in these patients (54 months), which is the critical period for recurrences to occur. This may therefore be a select lowrisk group, although a relatively short follow-up after fat grafting (mean, 32 months) was observed. Breast-conserving surgery for ductal carcinoma in situ was low for both the fat grafting and control arms (0.5 percent and 1.7 percent, respectively), although the rate of skin-sparing mastectomy was 57.6 percent for fat grafting and 49.0 percent for the control arm. In the ductal carcinoma in situ series reported by Petit et al., 39 six fat grafting patients and three control patients experienced recurrences (5-year cumulative incidence, 18 percent and 3 percent, respectively). All recurrences in both groups had either breast-conserving surgery or some form of skin-sparing mastectomy. Furthermore, the mean time interval between oncologic surgery and fat grafting in their series was relatively short, at 25 months, and the mean time to recurrence from fat grafting was 12 months. The rate of positive or close margins was 42 percent in the fat grafting group and 22 percent in the controls (p = 0.38), and there was no specific information provided regarding reexcisions or adjuvant radiotherapy for these patients. Margin control and early fat grafting intervention could be factors in the high locoregional recurrence rate observed in the fat grafting group in this series involving ductal carcinoma in situ patients. 39 In our series, all margins were clear.
In the series by Petit et al. (ductal carcinoma in situ), 39 the likelihood of a recurrence was greatest if fat grafting occurred within 24 months of the primary oncologic event. It is possible that early fat grafting may be associated with a greater risk of recurrence if performed in women with more risk factors for it. In this respect, our series may represent a low-risk group. Ihrai et al. 27 suggest a 36-month interval between primary surgery and fat grafting, and Riggio et al. 30 suggested a 55-month interval. The mean time to fat grafting in our series and that reported by Petit et al. 38 was similar ( Table 9 ). The mean time to recurrence was 12 months (range, 5 to 24 months) in the ductal carcinoma in situ series reported by Petit et al. 39 and 50 months for invasive cancer (range, 41 to 58 months) in the current series. There are limitations in interpreting individual studies reported in the literature. They are heterogeneous, retrospective, and nonmatched, and many include cosmetic breast patients without exposure to breast cancer. With respect to oncologic safety, it is important to focus on breast cancer patients only. 35, 36 Case matching supports the validity of the results. 24, 38 Confounding variables such as resection margins, cancer histology, and receptor status can also directly influence the outcome. The fat grafting and control groups in the current study are well matched (Tables 1  through 3) .
However, case series may yield helpful information if confounding variables are controlled for. Tables 10 and 11 give a summary of studies presenting data for patients previously treated for invasive breast cancer or ductal carcinoma in situ with fat grafting. Our review of 1573 patients reported in the literature shows no evidence of an increased risk of overall recurrence following fat grafting in terms of locoregional recurrence (0.95 percent per year) or distant metastases (1.01 percent per year). Reassuringly, most series report both locoregional recurrence and metastatic event rates between 1 and 2 percent per year. Petit et al. 39 found a locoregional recurrence rate of 3.2 percent per year in their case-controlled ductal carcinoma in situ study, which increased their overall locoregional recurrence.
Fat grafting is not a new technique, and has been exposed to criticism and controversy throughout its evolution. 5, [42] [43] [44] [45] [46] [47] In 1987, a position paper released by the American Society of Plastic and Reconstructive Surgeons Ad-Hoc Committee on New Procedures was "unanimous in deploring the use of fat injection in breast augmentation," as its radiologic sequelae would compromise the detection of breast cancer on surveillance mammography. 48 This issue has largely been resolved, as microcalcifications related to fat necrosis may be diagnosed after any type of breast cancer surgery and can be confidently distinguished from suspicious calcifications. 21, 22 Despite the "veil of silence" the American Society of Plastic and Reconstructive Surgeons article imposed, many surgeons were continuing to report on the use of fat grafting for breast augmentation and reconstruction. [5] [6] [7] [8] [9] 12, [14] [15] [16] 18, 21, 25 Coleman attempted to resolve these fears by advocating meticulous planning, "atraumatic liposuction," centrifugation, and graft placement to provide "pure, intact parcels of fat" to encourage integration and longterm graft survival. 1, 6, 7, 10, 11, 15, 16 He also became interested in the mechanisms of fat graft survival and stability, and postulated whether adipose-derived stems cells in the lipoaspirate may be involved, given their regenerative effect in experimental research and in "replenishing natural tissues." 7, 16 Consequently, in a cautious public statement, both the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery issued statements in 2007 that "strongly support the ongoing research efforts that will establish the safety and efficacy of the procedure." 13, 49, 50 Similarly, the French Society of Plastic, Reconstructive and Aesthetic Surgeons 51, 52 and the United Kingdom National Institute for Health and Care Excellence group 53 have issued caution with regard to fat grafting after breast cancer. These societies acknowledged the lack of high-level evidence in the literature demonstrating a link between fat grafting and breast cancer relapse. Based on recent reviews, the French have updated their recommendations, 52 and a phase III, multicenter, randomized, controlled trial is currently taking place in France with the goal of investigating this issue. 54 Despite some concerns, it seems that fat grafting is increasingly popular in breast surgery. 4, 55 In a questionnaire to surgeons in the United Kingdom, 69 percent of plastic surgeons (48 of 70) and 11 percent of breast surgeons (17 of 158) are using the technique. Most attitudes were positive, with over 60 percent of surgeons agreeing that the benefits of fat grafting outweighed the risks.
Similarly, the American Society of Plastic Surgeons has reported that 62 percent of their members regularly use fat grafting for reconstructive breast surgery. 4 Fat is a metabolically active tissue consisting of a heterogeneous cell population secreting cytokines, hormones, and growth factors. [56] [57] [58] [59] A fat graft specimen contains mature adipocytes and preadipocytes, also known as adipose-derived stem cells. 56, 58, 59 Adipose-derived stem cells have considerable angiogenic and antiapoptotic features and constitute 10 percent of the cell population; however, graft survival is largely dependent on them, given their huge proliferative contribution. 14, 40, [57] [58] [59] Adipocytes and adipose-derived stem cells release cytokines ("adipokines") to communicate with resident tissue for stimulating angiogenesis, reducing apoptosis, and modulating the immune response during tissue repair. 57, 58, 60, 61 The initial apprehension regarding fat grafting and cancer resurgence came from obesity studies observing altered adipokine signaling in resident adipocytes that could facilitate cancer initiation and progression. 62 These adipokines have been extensively studied, and include leptin, adiponectin, resistin, metalloproteinase 11, hepatocyte growth factor, adipocyte-derived collagen VI, interleukins, transforming growth factor-α, transforming growth factor-β, and vascular endothelial growth factor. 57, 58, [60] [61] [62] [63] [64] Concern was raised that placement of these physiochemical factors at the site of a previous tumor microenvironment may fuel the "tumor-stromal interaction" through autocrine, paracrine, and exocrine/endocrine signaling that can result in tumor recurrence 14, [56] [57] [58] [59] [60] [61] [64] [65] [66] and metastasis. 58, 67, 68 The direct influence of adiposederived stem cells on residual or dormant tumor cells has been investigated with variable results. Co-cultures of human epithelial and adenocarcinoma tumor cell lines with mesenchymal stem cells in murine in vitro 58, 67, 69 and in vivo 66, 68, 69 models resulted in increased tumor cell viability, enhanced proliferation, and reduced apoptosis of tumor cells. However, other groups found adipose-derived stem cells capable of inhibiting proliferation, down-regulating cell signaling, and abrogating tumor progression. [70] [71] [72] Zimmerlin et al. found that adipose-derived stem cells did not activate dormant cancer cells, but promoted residual active cancer cells into tumor growth and expansion. The group suggested that reconstructive therapy using adipose-derived stem cellaugmented whole fat should be postponed until there is no evidence of active disease and there are clear margins. 69 Local and systemic recurrence of breast cancer is observed at similar rates in our case-controlled series, and may occur irrespective of the fat grafting intervention. Local recurrence and metastasis may be a manifestation of residual cancer stem cell activation and dissemination for reasons largely unknown, although the underlying molecular microenvironment may play a role. 56, 60, 73 Longterm dormancy of cancer cells is a known phenomenon, but it is particularly evident in breast cancer patients in whom, even after 8 years of disease-free survival, a significant rate of late recurrence has been observed. 74, 75 This suggests that many cancer types can persist as "minimal residual disease" and that putative cancer stem cells can remain dormant for years but are reactivated by still unknown mechanisms, often leading to rapid disease progression after a latent period. 76, 77 The discordance between in vitro studies and clinical observations could be attributable to a number of reasons. The initial question of adipocytes secreting adipokines that could fuel cancer cell progression came from hypertrophied resident adipocytes in obese patients. This is different from the clinical setting regarding fat grafting, where normal adipocytes are transplanted into the breast in the mastectomy or prepectoral plane, and not into the parenchyma. In vitro and in vivo studies involve highly controlled microenvironments in constructed scaffolds or immunosuppressed animal models, with many variables accounted for or eliminated. Furthermore, these studies have variable results, with some adipokines stimulating cancer cell growth and other suppressing it. The human subject is more complex, and there may be additional unrecognized pathways that abrogate adipokine signaling after fat grafting into a previous cancer environment in the clinical setting.
As with any study, there are limitations with the current article. This type of study would be difficult to design and run prospectively. The retrospective nature of this study is one drawback but also facilitates adequate case matching. Case matching prospectively would be difficult because of the five variables requiring matching from entry into the study. If either of the two control patients had a recurrence before time B′ (fat grafting intervention of the study patient), they would need to be excluded, requiring that study patient also to be excluded, or two retrospective matches made at this point, rendering the study nonprospective in nature. The study is nonrandomized, although randomization would be difficult because of the lack of a comparable alternative to fat grafting, and patients tend to know the benefits of the procedure and will ask for it, particularly if it enhances their reconstructive option. The ideal candidate in which to study the oncologic safety of fat grafting is the breast conserving patient. In our study, there were low numbers of patients treated with breast-conserving surgery-approximately 16 percent in each arm (35 patients in the fat grafting group); however, in our mastectomy group, approximately half of the patients received either a skin-sparing or nipple-sparing mastectomy, with the small potential to leave breast tissue remaining. There is controversy surrounding fat grafting in patients with previous ductal carcinoma in situ, particularly those treated with breast-conserving surgery, created by the ductal carcinoma in situ article by Petit et al. 39 Our study cannot reliably contribute evidence to this question, as we had low numbers of ductal carcinoma in situ patients treated with breast-conserving surgery.
Despite these warnings from basic science, and our study's limitations, the current clinical study shows no evidence of increased oncologic risk associated with fat grafting in women previously treated for breast cancer. This evidence should be interpreted with other similarly casecontrolled studies in establishing safe indications for fat grafting in this setting.
